Fulcrum Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Fulcrum Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Fulcrum Therapeutics Inc
Rating: 2.18158325
Author: Trendlyne DVM scores

about

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule ...

7.39 -0.15 (-1.99%)

218.53% Gain from 52W Low

2.1M

XNAS Volume

High volume today

XNAS 19 Sep, 2025 5:30 PM (EDT)

Not Eligible

Expensive Valuation

9.8 / 100

Technically Bullish

77.4 / 100

1Yr Price target upside is 50%

7 analysts

Fulcrum Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Fulcrum Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule ...

218.53% Gain from 52W Low

High volume today

SWOT Analysis

Fulcrum Therapeutics Inc Live Price Chart